鼻腔、鼻咽部恶性淋巴瘤多药耐药基因表达的临床研究

Expression of Multidrug Resistance Gene of the Malignant Lymphoma at Nasalcavity or Pharynx Nasalis:A Clinical Study

目的:探讨多药耐药基因-1(MDR-1)表达产物P-糖蛋白(P-gp)在鼻腔、鼻咽部恶性淋巴瘤组织中表达的临床意义。方法:用S-P免疫组化染色方法,检测37例鼻腔、鼻咽部恶性淋巴瘤组织中P-gp表达情况,并与患者的初诊与复诊、原发部位、病理类型、免疫组化分型等不同组织中P-gp的表达及预后相关性进行分析。结果:P-gp表达阳性的是复诊患者87.5%(7/ 8)、鼻咽部患者70.0%(7/10),与初诊患者34.5%(10/29)、鼻腔部患者37.0%(10/27)相比,均有明显差异;P-gp阳性表达患者耐药率88.2%(15/17),与P-gp阴性表达患者耐药率10.0%(2/20)相比,有明显差异。结论:P-gp阳性表达对预测耐药及临床医师选药、制定方案提供科学依据。

OBJECTIVE： To discuss the clinical significance of the expression of P-glycoprotein （P-gp）, the multidrug resistance gene- 1 （MDR- 1） expression product in the malignant lymphoma of nasalcavity and pharynx nasalis. METHODS： The expression of P - gp in the malignancy lymphoma of nasalcavity and pharynx nasalis of 37 cases was detected by S - P Immunohistochemical staining, and its correlations with patents＇ first visit, return visit, original sites, pathological type, immunohistochemical typing and prognosis were analyzed. RESULTS： Positive P- gp expression appeared in 87.5% （7/8） of the patients for return visit vs. 34.5% （10/29） for first visit and 70.0% （7/10） with malignant lymphoma at pharynx nasalis vs. 37.0% （10/27） with malignant lymphoma at nasal cavity, all showing significant differences. There were also significant differences in drug resistance between the patients with positive P- gp expression and those with negative P gp expression （88.2% （15/17） vs. 10.0% （2/20）） . CONCLUSION： Positive P-gp expression serves as scientific basis for clinicians in predicating drug resistance and selecting drugs and establishing schemes.